Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …

Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the
type most often studied in prospective clinical trials. This review reports the trials that have …

9003 Background: First-line CP was FDA-approved in 2004 for unresectable MPM. Given
the role of inflammation in MPM and promising responses to PD-1 pathway blockade in …

Opinion statement Unresectable or relapsed malignant pleural mesothelioma (MPM) has
dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog …

© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017; 9 (3): 485-489 jtd.
amegroups. com treated with a MMT protocol consisting of extended pleurectomy and …

Simple Summary Malignant pleural mesothelioma (MPM) is an aggressive cancer with
limited therapeutic options. Pemetrexed plus platinum is a standard first-line therapy, but …

7020 Background: MPM median OS does not exceed 13 months with pem/CDDP doublet.
US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an …

Background Approved systemic treatments for malignant pleural mesothelioma (MPM) have
been limited to chemotherapy regimens that have moderate survival benefit with poor …

Background Management options for unresected malignant pleural mesothelioma (MPM)
are largely limited to palliative chemotherapy and best supportive care. This study sought to …

Background The purpose of this study is to assess the efficacy and safety of combination
chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural …